Home | Structured Search | Drug Resource
Find: within
West Nile Virus Disease > Prevention Author: Amy V. Bode, MD, MSPH; James J. Sejvar, MD; Anthony A. Marfin, MD, MPH
Editorial changes - 2008-08-28
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Clothes that cover extremities can prevent mosquito bites.
  • Standing water allows mosquito larvae to develop; small holes in screens can allow mosquitoes indoor access.
  • DEET and permethrin repel mosquitoes.
  • The peak biting times of Culex mosquitoes, the most common WNV vector, are before dawn and after dusk.
  • Integrated mosquito control programs decrease mosquito populations and, therefore, transmission of WNV.

Evidence:

  • A recent clinical review article stresses that covering extremities should decrease risk for mosquito exposure per expert recommendation (1).
  • Mosquitoes in the home, mosquito bites, and standing water were associated with WNV infection in two case-control studies of 393 cases of WNV meningoencephalitis in Romania in 1996 (2)
  • Classic work indicates that environmental monitoring and maintenance is associated with decreased arthropod-borne virus exposure (3).
  • In a household-based, seroepidemiologic survey conducted in New York in 1999, using a cluster sample of 677 individuals, more than 2 hours spent outdoors after dusk or before dawn was associated with increased WNV seropositivity; DEET use was associated with decreased WNV seropositivity (4).
  • DEET-based repellents provide longer protection against mosquitoes than other available products from a 2001 comparison of 16 available products (5).
  • Effective prevention depends on integrated arboviral surveillance and control programs per expert recommendation (6).

Comments:

  • Much of the research regarding the efficacy of decreasing mosquito bites as a primary prevention tool is derived from older studies of malaria, Japanese encephalitis, and St. Louis encephalitis and has not been specifically evaluated for WNV.
  • No vaccine for WNV currently exists for humans.
  • In addition to the preventive efforts of individuals, physicians, and patients, local jurisdictions implement vector control programs.

FAQs
Amy V. Bode, MD, MSPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Anthony A. Marfin, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Carrie Nielsen, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. James J. Sejvar, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.